


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claim 1 (original): A combination for simultaneous, separate or sequential use which comprises (a) a cyclin-dependent kinase inhibitor and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide having the formula I



(I)

in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier.

Claim 2 (original): A combination for simultaneous, separate or sequential use which comprises (a) a cyclin-dependent kinase inhibitor and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide having the formula I in which the active ingredients (a) and (b) are present in a synergistically effective amount in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier.

Claim 3 (currently amended): Use of a combination according to claim 1 or 2 in the treatment of a tumor disease.

Claim 4 (currently amended): Use of a combination according to ~~any one of claims 1 or 2~~ claim 1 for the preparation of a medicament in the treatment of a tumor disease.

Claim 5 (currently amended): Use of a combination according to claim 3 or 4 wherein the tumor disease is leukemia.

Claim 6 (currently amended): Use of a combination according to ~~any one of~~ claim 5 wherein the leukemia is a Bcr/Abl-positive leukemia.

Claim 7 (original): Use of a combination according to claim 6 wherein the Bcr/Abl-positive leukemia is a compound of formula I-resistant leukemia.

Claim 8 (original): Use of a combination according to claim 7 wherein the Bcr/Abl-positive leukemia resistant to compound of formula I over-expresses Bcr/Abl.

Claim 9 (currently amended): Use or combination according to ~~any one of claims 1 to 8~~ claim 1 wherein the cyclin-dependent kinase inhibitor is selected from the group consisting of purine-based derivatives, pyrimidine-based derivatives, benzenesulfonamides, flavonoids, thiazole derivatives, paullone derivatives, staurosporine derivatives, indigoid bisindoles, butyrolactone 1, pyrazolopyridine compounds, indol derivatives and amino-pyrazole compounds.

Claim 10 (currently amended): Use or combination according to ~~any one of claims 1 to 9~~ claim 1 wherein the cyclin-dependent kinase inhibitor is flavopiridol or E 7070 or CYC 202.

Claim 11 (currently amended): Use or combination according to ~~any one of claims 1 to 10~~ claim 1 wherein the cyclin-dependent kinase inhibitor is flavopiridol.

Claim 12 (original): Use or combination according to claim 11 wherein flavopiridol and 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide are present in a synergistically effective molar ratio (FP/COMPOUND I) range of 1:1 to 1:10.

Claim 13 (currently amended): A method of treating a warm-blooded animal having a proliferative disease comprising administering to the animal a combination according to ~~any one of claims 1 to 12~~ claim 1 in a quantity which is jointly therapeutically effective against said proliferative disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

Claim 14 (currently amended): A method of inhibiting the formation of metastases in a warm-blooded animal having a tumor disease which comprises administering to the patient a pharmaceutically effective amount of a combination according to ~~any one of claims 1 to 13~~claim 1 in a quantity which is jointly therapeutically effective against said tumor disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

Claim 15 (currently amended): A pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a tumor disease of a pharmaceutical combination according to claim 1 to 12 and at least one pharmaceutically acceptable carrier.

Claim 16 (currently amended): A commercial package comprising a combination according to ~~any one of claims 1 to 12~~claim 1 together with instructions for simultaneous, separate or sequential use thereof in the treatment of a proliferative disease.